A phase Ib KEYNOTE-028 trial conducted to evaluate the safety and efficacy of pembrolizumab, an anti-PD-L1 antibody, evaluated patients with advanced differentiated thyroid cancer expressing programmed cell death ligand 1 (PD-L1) [4]. This evidence concerns the gene CD274 and differentiated thyroid carcinoma.